Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

KOD

+ Watchlist+ Portfolio

Kodiak Sciences Inc

Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$96.80
52-Week Range
$19.04 – $112.79
Market Cap
$6.40B
P/E (TTM)
—
EPS (TTM)
-4.08
Dividend Yield
0.00%
Advanced Metrics
Price/Book
499.03
PEG Ratio
—
Return on Equity
-1360.91%
Return on Assets
-74.56%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
1.70
Debt/Equity
3.70
Total Debt
$46.56M
Free Cash Flow
$-70.67M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$6.34B

Market Snapshot

About

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic retinal diseases. The company's proprietary platform focuses on developing longer-lasting treatments for conditions like wet age-related macular degeneration and diabetic retinopathy. Kodiak's lead product candidate is designed to reduce treatment burden through extended dosing intervals.